Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Protect Info for Off-Patent Brands Even after Market Exit: JEMA
The Japan Established Medicine Association (JEMA) on May 25 issued a proposal calling for the creation of a clear rule to protect and continue to provide information pertaining to off-patent brand-name medicines even after they withdraw from the market. “Information…
To read the full story
Related Article
- JEMA Raises Alarm on Drug Loss of Complex Generics, Urge Development Incentives
December 11, 2023
- Ease API Regulations to US and European Levels to Stop Generic Woes: JEMA
December 15, 2022
- JEMA Calls for Disclosure of Expected 3-Month Inventory Levels, Smaller Number of Companies per API
December 2, 2021
ORGANIZATION
- Novartis’ Pullicino to Helm EFPIA Japan from July
May 22, 2026
- FPMAJ Calls for Greater Support for Stable Drug Supplies in Honebuto Policy
May 22, 2026
- JPMA Exec Urges Broader Debate on Japan’s CEA System
May 22, 2026
- COVID-19 Vaccination Rates Fall as Out-of-Pocket Costs Rise: Jiji Survey
May 21, 2026
- Awareness of HPV Vaccination for Males Stands at 39.4%: Survey
May 21, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…